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osteolytic or osteosclerotic bone lesions were detectable. HHV-8
DNA was no longer detectable in marrow or blood. The patient
received 4 cycles of idarubicine/dexamethasone. The response to
this treatment was minimal and an ASCT was planned. After
mobilisation chemotherapy with iphosphamide, epirubicine and
etoposide, 29.65 x 106 CD34-positive progenitor cells/kg could be
harvested with one leukapheresis. ASCT was performed after high
dose therapy with melphalan 200 mg/m2. Reinfusion of 14.83 
106 CD34-positive progenitor cells/kg and medication with G-
CSF resulted in engraftment on day 9. Restaging 5 weeks later
showed an excellent response. Bone marrow plasma cell inﬁltration
was no longer detectable and hypercellularity of megakaryopoesis
was markedly reduced. The platelet counts had returned to normal
and the pleural effusions had vanished. IgG and serum electro-
phoresis were normal while the immunoﬁxation remained positive
for IgG lamda. The polyneuropathy of the patient is continuously
improving. In conclusion, this case may represent an evolution
from possibly HHV-8 related POEMS syndrome to multiple my-
eloma. Despite lack of response to standard chemo- and immuno-
therapy ASCT seems to be a useful therapeutic option in patients
with signs of POEMS syndrome.
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RNA-LOADING OF CMRF-56 POSITIVE BLOOD DENDRITIC CELLS IS A
PROMISING STRATEGY FOR MULTIPLE MYELOMA IMMUNOTHERAPY
Turtle, C.J.1, Radford, K.J.1, Allan, C.P.1, Kassianos, A.1, Kato, M.1,
Vuckovic, S.1, MacDonald, K.J.1, Lopez, J.A.2, Jackson, D.C.3, Wright,
S.4, Taylor, K.4, Marlton, P.5, Gill, D.5, Hart, D.N.J.1 1. Mater
Medical Research Institute, Brisbane, QLD, Australia; 2. Queensland
Institute of Medical Research, Brisbane, QLD, Australia; 3. University
of Melbourne, Melbourne, VIC, Australia; 4. Mater Adult Hospital,
Brisbane, QLD, Australia; 5. Princess Alexandra Hospital, Brisbane,
QLD, Australia
Immunologic responses to the malignant plasma cells of multiple
myeloma (MM) patients are beinginvestigated for their ability to
prevent disease relapse after autologous and allogeneic haemato-
poietic stem cell transplantation. Dendritic cells (DC) are special-
ized leukocytes that have the capacity to prime and direct an
immune response against tumour-associated antigens (TAA). We
have used new Trucount® technology to evaluate the whole blood
DC subset composition of healthy donors and MM patients. MM
donors have similar numbers of CD11c CD16 and
CD11cCD16-blood DC subsets but about half the number of
CD11c-CD123 blood DC compared to normal donors. A
CMRF-56 monoclonal antibody-based immunomagnetic selection
procedure was used to enrich blood DC for functional studies from
the peripheral blood mononuclear cells of healthy donors and MM
patients. CMRF-56 blood DC from MM patients are efﬁciently
activated ex vivo and induce autologous and allogeneic mixed lym-
phocyte responses. The CMRF-56 blood DC preparation is able
to present MHC class I -restricted peptide antigens and has been
used to generate cytotoxic T lymphocytes (CTL) against MM
-related TAA, hTERT and MUC1. We have optimised the load-
ing of CMRF -56 blood DC preparations with antigen-encoding
mRNA and have shown that enhanced green ﬂuorescent protein
mRNA is rapidly transl ated after electroporation into blood DC.
In addition, inﬂuenza matrix protein (FMP) mRNA -loaded blood
DC can process and present antigen to FMP-speciﬁc CTL clones
and prime FMP-speciﬁc CTL responses in whole PBMC popula-
tions. We are currently in the process of generating responses
against total RNA extracted from MM cell lines prior to initiating
a clinical trial of RNA-loaded CMRF-56 blood DC in patients.
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FREELITE; A NEW LABORATORY TOOL TO AIDE IN MONITORING
MULTIPLE MYELOMA AFTER TREATMENT
Staggs, B., Fender, B., Joseph, L. University of Arkansas for Medical
Sciences, Little Rock, AR
Background: Multiple Myeloma (MM) is a diagnosis based on
multiple parameters. Immunoglobulin levels, radiography, and
bone marrow morphology are all evaluated for diagnosis and dis-
ease monitoring. Each test examines a different aspect of the
disease. Conﬂicting values between these can obscure the disease
picture. In addition, there are several subsets of MM depending on
the immunoglobulin secreted. However, one thing is common to
all but 5% of MM patients; an excess of free light chains is
produced. A new laboratory test, Freelite™, easily and accurately
measures free light chains in the serum. Methods: One hundred
ﬁfty patients with MM who had undergone treatment, some in-
cluding bone marrow transplant, were prospectively examined.
Fifty were patients treated for free light chain MM. Seventy-two
were patients treated for IgG MM and 28 were patients treated for
IgA secreting MM. The current serum free light chains were
examined using Freelite™ and then correlated to the disease state
as identiﬁed by consensus of bone marrow biopsy, ﬂow cytometry
and electrophoresis. Results: Thirty-seven of the 50 patients
treated for free light chain MM currently had disease. All 37 had
markedly elevated serum free light chain levels. The 13 remaining
patients were diagnosed “negative” or “atypical” and 8 of these had
elevated serum free light chain levels. Forty-six of 100 patients
treated for IgG or IgA MM currently had disease. All 46 of these
had elevated serum free light chain levels. Fifty-four were diag-
nosed “negative” or “atypical” and 30 had elevated serum free light
chain levels. Discussion: In this broad analysis of the most com-
mon subtypes of MM, Freelite™ is 100% sensitive when correlated
to MM diagnosed by our standard methods. The issue then be-
comes the decreased speciﬁcity (43%) due to false positives that are
seen in every subset. This may well be detection of recurrent or
residual disease not seen by our standard methods. Only close
follow-up will determine if these “false positive” patients recur
before the “true negative” patients. This sensitive and quick serum
analysis may prove to be an excellent tool for monitoring MM
patients after treatment.
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AUTOLOGOUS VERSUS ALLOGENEIC STEM CELL TRANSPLANT FOR
MULTIPLE MYELOMA
Arora, M., McGlave, P.B., Burns, L.J., Miller, J.S., Barker, J.N.,
Defor, T.E., Weisdorf, D.J. University of Minnesota, Minneapolis, MN
We report results of a comparative analysis of 87 patients with
multiple myeloma, treated with either autologous PBSCT (n 70)
or allogeneic sibling donor myeloablative transplant (n 17) using
cyclophosphamide and fractionated TBI conditioning. Autologous
transplant recipients were signiﬁcantly older (median age 53 vs. 47
years, p  .01) and had a longer period between diagnosis and
transplant (10.5 vs 7 months, p .03). Autologous transplant led to
lower transplant related mortality (TRM) of 4% (95% CI 0-36%)
vs. 18% (0-9%) in the allogeneic patients at 100 days post trans-
plant (p  .02). More frequent complete responses (CR) were seen
in the allogeneic patients (64% (95%CI 37-91%) vs. 34% (95%CI
23-45%) in the autologous patients, p  .09). In the autologous
patients, overall survival of 86% (95% CI 80-95%) at one year and
50% (95% CI 47-75%) at 4 years was seen vs. 64% (95% CI
40-87%) at one year and at 4 years in the allogeneic patients. In
patients surviving beyond one year, survival was superior in the
allogeneic transplant patients (100% (95% CI 100-100%) versus
58% (95% CI 41-75%) at 4 years, p  .02). The cumulative
incidence of relapse showed a trend towards higher relapse in the
autologous patients (73% (95% CI 55-90%) versus (37% (95% CI
11-63%) in allogeneic patients at 4 years, p  .1). In multiple
regression analysis, attainment of a CR or PR pre transplant (OR
3.4, 95% CI 0.9-12.9, p  .06),  1 year between diagnosis and
transplant (OR 3.8, 95% CI 1.1-13.8, p  .04),  2 regimens of
chemotherapy (OR 8.3, 95% CI 2.2-31.3, p .01) were associated
with good response. Early transplant with 4 chemo cycles (RR of
failure 0.5 (95% CI 0.2-0.9, p  0.04) and attainment of CR or PR
post transplant (RR 0.4 (95% CI 0.2-0.7, p  0.01) was a signiﬁ-
cant predictor of good overall and progression free survival. Older
age at transplant (RR 1.1, 95% CI 0.9-1.3, p  .06), allogeneic
transplant (RR 11.0, 95% CI 2.3-53.7, p  .01), and  4 cycles of
pretransplant chemotherapy (RR 6.3, 95% CI 1.1-35.7, p  .04)
were each signiﬁcant predictors of high TRM. We observed good
clinical tolerance of the myeloablative conditioning regimen fol-
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lowed by either autologous or allogeneic transplant. We report
modest TRM, high CR rates and favorable survival following
allogeneic transplants. Younger patients with responsive disease
undergoing early transplant may have a superior survival and lower
TRM. This group may be suitable candidates for allogeneic trans-
plant.
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DOSE-INTENSIFICATION AND STEM CELL TRANSPLANTATION (SCT)
FOR HISTOLOGICALLY TRANSFORMED LOW-GRADE FOLLICULAR NON-
HODGKIN LYMPHOMA (NHL): A SINGLE CENTER EXPERIENCE
Vusirikala, M.1, Brandt, S.1, Chinratanalab, W.1, Greer, J.P.1, Ja-
gasia, M.1, Kassim, A.1, Mineshi, S.1, Morgan, D.S.1, Ruffner, K.1,
Friedrich, S.G.1, Shyr, Y.2, Goodman, S.A.1 1. Division of Hematology/
Oncology, Vanderbilt University Medical Center and Veterans Admin-
istration Medical Center, Nashville, TN; 2. Department of Biostatistics,
Vanderbilt University Medical Center, Nashville, TN
Introduction: Histological transformation of low-grade follicu-
lar NHL to a higher grade occurs in greater than 50% of patients
during the course of their disease. Historically, prognosis of these
patients is poor following conventional chemotherapy with median
survival of less than a year. SCT following dose intensiﬁcation has
been shown in few studies to improve the survival in such patients.
Methods: We performed a retrospective review of the pathology
of 367 adult NHL patients who underwent high-dose chemother-
apy and SCT at our institution between 1992 and 2002. We
identiﬁed 34 patients with follicular low-grade NHL who had
transformed to intermediate grade disease (diffuse large cell or
transformed large cell-REAL grade III). Patients with transforma-
tion to high grade or immunoblastic NHL were excluded. Results:
Thirty-one patients underwent autologous and 3 underwent allo-
geneic SCT. Median age at transplant was 53 years (35-69). 70% of
patients were male. 26% (9/34) patients had transformed disease at
diagnosis (had concurrent low-grade histology) and 74% (25/34)
had transformation at ﬁrst relapse. The median time to transfor-
mation from low to intermediate grade was 930 days (630-5430
days). 85% of the patients had advanced disease (stage III-IV) at
transformation. Median number of treatments for transformed
disease prior to SCT was 2 (1-6). 24 patients were in a partial
remission (PR), 6 in a complete remission (CR) and 4 had stable
disease at time of SCT. 76% (26/34) patients received a non-TBI
based conditioning regimen; 85% received peripheral blood stem
cells with a median CD34 dose of 3.45  106/kg. All patients
showed normal engraftment. Survival at 100 days was 97%
(95%CI 91%-100%), the only peri-SCT death occurred in the
allogeneic group. Median overall survival (OS) from SCT was 48
months (95%CI 38 mo-not reached) and 4-year OS was 49%.
Median disease free survival (DFS) from SCT was 20 months
(95%CI of 10-57months) with a 4-year DFS of 18%. The number
of prior therapies and time to transformation had no impact on the
survival. Subgroup of patients with stable disease (no response to
chemotherapy) prior to SCT had the worst outcome. Conclusion:
Our survival data indicates that one-half of patients with trans-
formed NHL will survive 4 years and one third of the survivors will
be disease free. SCT should be considered for eligible patients with
chemosensitive histologically transformed NHL.
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UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION AF-
TER NONMYELOABLATIVE CONDITIONING FOR PATIENTS WITH POOR
RISK, RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Georges, G.E.1, Maris, M.B.1, Sandmaier, B.M.1, Stuart, M.J.2, Nied-
erwieser, D.3, Agura, E.4, Bruno, B.5, McSweeney, P.6, Anasetti, C.1,
Storb, R.1, Maloney, D.G.1 1. Fred Hutchinson Cancer Research Center
and Univerisity of Washington, Seattle, WA; 2. Stanford University,
Palo Alto, CA; 3. University of Leipzig, Germany; 4. Baylor University,
Dallas, TX; 5. University of Torino, Italy; 6. University of Colorado,
Denver, CO
We investigated the feasibility of HLA-matched unrelated donor
(URD) hematopoietic cell transplantation (HCT) in patients with
advanced stage, poor-risk multiple myeloma after nonmyeloabla-
tive conditioning. Eighteen patients, median age 53 years (range,
29-66), were enrolled between 5/2000 and 12/2002. At study entry,
12 patients had relapsed/refractory disease after a preceding autol-
ogous HCT, 5 patients had refractory disease following multiple
standard chemotherapy regimens, and 1 patient achieved a partial
remission (PR) after standard chemotherapy. Nine patients under-
went a planned high dose autologous HCT (Melphalan 200 mg/
m2) a median of 75 days prior to URD HCT, including 4 of the 12
patients with relapsed/refractory disease after prior failed autolo-
gous HCT. Two of the 18 patients were in complete remission
(CR, IBMTR/ABMTR criteria) immediately prior to URD HCT.
Nonmyeloablative conditioning consisted of ﬂudarabine (30 mg/
m2  3 days) and 2 Gy total body irradiation. A median of 8.6 
106 CD34/kg G-CSF-stimulated peripheral blood mononuclear
cells were transplanted from URDs matched for HLA-A, -B, -C
antigens and -DRB1 and -DQB1 alleles. Postgrafting immunosup-
pression included mycophenolate mofetil and cyclosporine. Dura-
ble engraftment was achieved in 17 of 18 patients. Acute GVHD
occurred in 13 (72%) patients and was exclusively grades II and III
in 11 and 2 patients, respectively. Chronic extensive GVHD oc-
curred in 11/16 (69%) of evaluable patients. After allografting, 7
patients (39%) achieved CR and 3 (17%) achieved PR, for an
overall response rate of 56%. Three patients (17%) died of pro-
gressive disease and 4 patients (22%) died of non-relapse causes at
a median of 5 months after URD HCT. With a median follow-up
of 15 months after URD HCT, 11 of 18 patients (61%) were alive,
6 (33%) in CR, 2 (11%) in PR and 3 (17%) with stable disease
(SD). Of the 9 patients who underwent a planned high dose
autologous HCT followed by URD HCT, 7 were alive: 5 in CR,
1 in PR and 1 with SD. In summary, URD HCT after nonmy-
eloablative conditioning is feasible with a relatively low non-re-
lapse mortality and provides a high response rate for patients with
relapsed or refractory multiple myeloma. The data also suggest
that intensive cytoreductive therapy (autologous HCT) followed
by URD HCT may be an effective salvage approach for treating
patients with poor risk, chemotherapy refractory multiple my-
eloma or after failed prior autologous HCT.
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NO ADVANTAGE FOR MORE THAN 4 CYCLES OF VAD PRIOR TO AU-
TOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA
Rodriguez, C.P., Bolwell, B., Ronald, S., Pohlman, B., Rybicki, L.,
Kalaycio, M.E. Department of Hematology and Medical Oncology,
Cleveland Clinic Foundation, Cleveland, OH
Patients with myeloma are typically treated with several cycles of
infusional vincristine, doxorubicin and dexamethasone (VAD)
prior to autologous stem cell transplant. We reviewed our experi-
ence to determine if an optimal number of VAD cycles (Vincristine
0.4 mg/day IV days 1-4, Doxorubicin 9mg/m2/day IV days 1-4,
Dexamethasone 40mg PO days 1-4, 9-12, 17-20) could be identi-
ﬁed. The records of 95 patients who underwent autologous pe-
ripheral stem cell transplantation for multiple myeloma from 1989
to 2001 were reviewed. Data on each patient’s pretransplant che-
motherapy regimen, response to initial chemotherapy and toxicity
during transplantation were obtained. Seven patients who suffered
relapse after initial chemotherapy were excluded during the data
analysis. The Kaplan Meier method was used to estimate survival
in the remaining 88 patients. Of the 88 patients treated, 62 were
treated with VAD for a median of 4 cycles (range 1-9) before
transplant. Thirty six patients were treated with 4 cycles of VAD,
9 were treated with less than 4 cycles, 15 received more than 4
cycles and two received an unknown number of cycles. Fourteen
patients received VAD either before of after other chemotherapy
regimens. Of the 26 patients who were treated with regimens other
than VAD, most included melphalan. One patient received an
unknown type of chemotherapy. Patients had to demonstrate at
least a partial remission in order to proceed with transplantation.
Autologous stem cells were harvested after GCSF mobilization. All
patients were admitted to the hospital and were treated with Busul-
fan (1mg/kg every 6 hours for 16 doses, days 1 to 4) and Cyclo-
phosphamide (60 mg/kg daily for 2 doses). GCSF was given after
transplant in addition to other standard supportive care practices.
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